This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The BMS spirocyclobutene-containing FXR agonist, BMS-986318, appears to have been intended as a clinical candidate, but was withdrawn from a planned Ph. I…
molecule
2 years ago ●
1 min read
The Takeda MAGL inhibitor, “compound 4f”, was selected by reviewer Joachim Rudolph. “MAGL (monoacylglycerol lipase) is implicated in neuroinflammation, and inhibitors of…
molecule
2 years ago ●
1 min read
The Merck CETP inhibitor backup, MK-8262, is potential best-in-class CETP inhibitor, which was only discontinued as a backup due to the…
molecule
2 years ago ●
1 min read
The Zentalis Wee1 inhibitor, ZN-c3, is a highly selective kinase inhibitor that is currently being evaluated in Ph. II clinical trials…
molecule
2 years ago ●
1 min read
The Bayer DNA-PK inhibitor, BAY-8400, is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics…
molecule
2 years ago ●
1 min read
The Xenon NaV1.6 Inhibitor, NBI-921352, is remarkably selective for the NaV1.6 sodium channel over other isoforms (IC50 = 51 nM, 756x…
molecule
2 years ago ●
1 min read
Load More
